Sage Journals: Discover world-class research

Abstract

Keywords

Cladribine multiple sclerosis liver injury hepatotoxicity

Get full access to this article

View all access options for this article.

References

Pfeuffer

Rolfes

Hackert

, et al. Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Mult Scler 2022; 28(2): 257–268.

European Medicines Agency. Mavenclad (cladribine) – Risk of serious liver injury and new recommendations about liver function monitoring, https://www.ema.europa.eu/en/medicines/dhpc/mavenclad-cladribine-risk-serious-liver-injury-new-recommendations-about-liver-function-monitoring

Medicines and Healthcare products Regulatory Agency. Cladribine (Mavenclad): New advice to minimise risk of serious liver injury, https://www.gov.uk/drug-safety-update/cladribine-mavenclad-new-advice-to-minimise-risk-of-serious-liver-injury

Saraceno

Pirro

Stigliano

, et al. Acute idiosyncratic liver injury after cladribine treatment for multiple sclerosis: First case report and review on associated hepatic disorders. Mult Scler 2022.

Nociti

Biolato

De Fino

, et al. Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain Behav 2018; 8(6): e00968.

Cladribine-induced liver injury: Implications for practice

Abstract

Keywords

Get full access to this article

References